Lucrezia Pisanu, Marianna Russo, Maria Arminio, Lorenzo Arlando, Valentina Conio, Francesco Rocco Bertuccio, Klodjana Mucaj, Mitela Tafa, Giulia Maria Stella, Angelo Guido Corsico
{"title":"Management of severe pneumonia in respiratory non-intensive care unit: a retrospective study from a single center experience.","authors":"Lucrezia Pisanu, Marianna Russo, Maria Arminio, Lorenzo Arlando, Valentina Conio, Francesco Rocco Bertuccio, Klodjana Mucaj, Mitela Tafa, Giulia Maria Stella, Angelo Guido Corsico","doi":"10.3389/fmed.2025.1666800","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Severe pneumonia management in the hospital setting often relies heavily on established clinical practice and physician experience. This approach has the purpose of enabling early identification of risk factors most strongly associated with severe pneumonia at the time of hospital admission.</p><p><strong>Methods: </strong>This retrospective study analyzed inpatients with pneumonia treated in a Respiratory disease unit, stratifying them into two groups-severe and non-severe pneumonia - according to the 2007 IDSA/ATS criteria, identifying differences in demographic profiles, clinical features, treatment strategies, and prognostic outcomes.</p><p><strong>Results: </strong>Out of a cohort of 302 patients, 26 (8.6%) met the criteria for severe pneumonia. A statistically significant difference was observed in the Pneumonia Severity Index (PSI > 90), recorded in 61.53% of patients with severe pneumonia compared to 41.31% in non-severe cases. The Charlson Comorbidity Index (CCI ≥ 4), indicative of lower 10-year survival due to comorbidities, was significantly more frequent in the severe group (84.61% vs. 61.23%). Microbiological analysis of bronchoalveolar lavage (BAL) showed a positivity rate of 75% in the severe group versus 35.48% in the non-severe group (<i>p</i> < 0.05). Significant differences were also found in the use of respiratory support: high-flow nasal cannula (HFNC) was used in 69.23% of severe cases versus 32.97% in non-severe cases, while CPAP was administered in 23.07% versus 5.43%, respectively. Finally, antibiotic therapy was significantly longer in the severe group, with a mean duration of 14.69 days compared to 11.77 days in non-severe patients, involving both intravenous and oral regimens as part of initial or sequential treatment.</p><p><strong>Conclusion: </strong>Timely recognition of these factors is essential to ensure optimal patient care, facilitate close monitoring of critically ill individuals, allow for prompt therapeutic escalation, and support ICU admission when needed. This analysis highlights the need for a critical reassessment of existing guidelines and underscores the value of integrating them with real-world clinical experience.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1666800"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488406/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1666800","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Severe pneumonia management in the hospital setting often relies heavily on established clinical practice and physician experience. This approach has the purpose of enabling early identification of risk factors most strongly associated with severe pneumonia at the time of hospital admission.
Methods: This retrospective study analyzed inpatients with pneumonia treated in a Respiratory disease unit, stratifying them into two groups-severe and non-severe pneumonia - according to the 2007 IDSA/ATS criteria, identifying differences in demographic profiles, clinical features, treatment strategies, and prognostic outcomes.
Results: Out of a cohort of 302 patients, 26 (8.6%) met the criteria for severe pneumonia. A statistically significant difference was observed in the Pneumonia Severity Index (PSI > 90), recorded in 61.53% of patients with severe pneumonia compared to 41.31% in non-severe cases. The Charlson Comorbidity Index (CCI ≥ 4), indicative of lower 10-year survival due to comorbidities, was significantly more frequent in the severe group (84.61% vs. 61.23%). Microbiological analysis of bronchoalveolar lavage (BAL) showed a positivity rate of 75% in the severe group versus 35.48% in the non-severe group (p < 0.05). Significant differences were also found in the use of respiratory support: high-flow nasal cannula (HFNC) was used in 69.23% of severe cases versus 32.97% in non-severe cases, while CPAP was administered in 23.07% versus 5.43%, respectively. Finally, antibiotic therapy was significantly longer in the severe group, with a mean duration of 14.69 days compared to 11.77 days in non-severe patients, involving both intravenous and oral regimens as part of initial or sequential treatment.
Conclusion: Timely recognition of these factors is essential to ensure optimal patient care, facilitate close monitoring of critically ill individuals, allow for prompt therapeutic escalation, and support ICU admission when needed. This analysis highlights the need for a critical reassessment of existing guidelines and underscores the value of integrating them with real-world clinical experience.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world